Revisions for SOBERANA PEDIATRIA CLINICA 1 | Registro Público Cubano de Ensayos Clínicos

Comparing two revisions:

Revision of 8 January 2026 - 5:56am:

SOBERANA PEDIATRIA CLINICA 1

General information

Section to complete general information about the trial: scientific and public title, protocol identifiers, sponsors and Source(s) of Monetary or Material Support.

Acronym of Public Title:

SOBERANA PEDIATRIA CLINICA 1

Scientific title:

Exploratory and open study, to evaluate the safety, reactogenicity and immunogenicity, of a heterologous scheme of two doses of the prophylactic anti SARS vaccine candidate - CoV - 2, FINLAY-FR-2 and one dose of FINLAY-FR-1A, in Cuban children and adolescents (COVID-19)

Acronym of Scientific Title:

SOBERANA PEDIATRIA CLINICA 1

Secondary indentifying numbers:

IFV/COR/13

Issuing authority of the secondary identifying numbers:

Instituto Finlay de Vacunas (IFV)

Source(s) of monetary or material support:

Finlay Vaccine Institute (IFV); Cuban Fund for Science and Innovation (FONCI) from Ministry of Science, Technology and Enviroment CITMA)

Authorization for beginning

Section to complete information about the regulatory approval of clinical trial: regulatory agency name, approval date and reference number in the agency.

Regulatory instance to authorize the initiation of the study:

Center for State Control of Drugs, Medical Devices and Equipment (CECMED)

Reference number:

In process

Principal investigator

Section to complete information about Email address, telephone number and postal address of the Principal Investigator.

First name:

Maria

Midle name:

Eugenia

Last name:

Toledo Romani

Medical Specialty :

First degree specialist in Integral General Medicine. Doctor of Medical Science

Affiliation:

Institute of Tropical Medicine "Pedro Kouri"

Postal address:

Novia del Mediodia avenue, KM 6 1/2, La Lisa

City:

Havana

Country:

Cuba

Zip Code:

11400

Telephone:

+53-72020427

Email address:

mariaeugenia@ipk.sld.cu

Clinical sites to participate

Section to complete the data related to the clinical sites involved in the trial: site and responsible investigator for every site.

Countries of recruitment:

Cuba

Clinical sites:

Havana, Clinica 1 La Lisa, Leslyhana Verdecia Sanchez, MD. Specialist in Internal Medicine

Recruitment status

Section to complete information about the recruitment status and the date of first enrolment subject

Recruitment status:

Recruiting

Date of first enrollment:

17/07/2021

Health condition and Intervention

Section to complete information about the primary medical condition(s) or problem(s) studied and, a characteristics of the intervention(s).

Health condition(s) or Problem(s) studied:

COVID-19

Health condition(s) code:

Disease Prevention

Coronavirus Infections

SARS Virus

Coronaviridae Infections

Betacoronavirus

Pediatrics

Health condition keyword:

COVID-19

SARS-CoV2

Intervention(s):

Experimental Group: FINLAY-FR-2, 25 µg of RBD-TT / alumina, Intramuscular (IM), 0.5 mL, 0 - 28 days. Presentation: Vial with single dose / Vial with multidose of 10 doses + FINLAY-FR-1A, 50 µg of d-RBD / alumina, Intramuscular (IM), 0.5 mL as a 56-day booster dose. Presentation: Vial with single dose

Intervention code:

Immunogenicity, Vaccine

Immunotherapy, Active

Vaccination

Injections, Intramuscular

Intervention keyword:

SOBERANA

Outcomes and Timepoint

Section to complete information about primary and secondary outcomes including. It includes the metric or method of measurement used and, the time point for every outcome.

Primary outcome(s):

Serious Adverse Events-SAE (It will measure as: -Occurrence of the SAE (Yes, No), - Duration (Time from start date until end date of event), -Description of the event, Result (Recovered, Recovered with squeals, Persists, Death, Unknown), - Causality (Causal association consistent with vaccination, Undetermined, Inconsistent causal association with vaccination, not classifiable). Measurement time: daily for 28 days after each dose.

Key secondary outcomes:

1) Solicited Local and systemic Adverse Events (AE) (They will measure as: -Occurrence of the AE (Yes, No), Duration (Time from start date until end date of event), -Intensity of the AE (mild, moderate, severe), -Severe (Serious, not serious), -Result (Recovered, Recovered with sequelae, Persists, Death, Unknown), -Causation (causal association consistent with vaccination, Indeterminate, causal association inconsistent with vaccination, not classifiable)). Measurement time: daily for 7 days after each dose. 2) Unsolicited Adverse Events (AE) (They will measure as: Description of the AE (name of the event), Duration (Time from start date until end date of event), -Intensity of the AE (mild, moderate, severe), -Severe (Serious, not serious) , -Result (Recovered, Recovered with sequelae, Persists, Death, Unknown), -Causality (causal association consistent with vaccination, Undetermined, causal association inconsistent with vaccination, not classifiable)). Measurement time: daily for 28 days after each dose . 3) Concentration of specific anti-RBD IgG antibodies. Measurement time: Day 70. 4) Neutralizing antibody titer: Measurement time: Day 70. 5) % ACE2-RBD inhibition: Measurement time: Day 70.

Selection criterias

Section to complete information about the inclusion and exclusion criteria for participant selection, including age and gender.

Gender:

Male/Female

Minimum age:

3 years

Maximum age:

18 years

Inclusion criteria:

1) Subjects aged between 3 and 18 years. 2) Voluntariness expressed through informed consent to participate in the study: - Subjects aged 3-11 years: Informed consent of the father, mother or legal guardian. - Subjects aged 12-18 years: Informed Consent of the father, mother or legal guardian and Informed Assent of the adolescent. 3) General, regional and apparatus physical examination without alterations.

Exclusion criteria:

1) Subjects with acute febrile or infectious disease at the time of the vaccine application or in the 7 days prior to its administration. 2) Subjects meeting any of the following criteria: a) Previous or current history of SARS-CoV 2 infection. b) Being declared in the contact or suspect category at the time of inclusion. 3) Subjects with a history of hypersensitivity to Thimerosal or any of the components of the formulations. 4) Subjects with a history of having been immunized with a vaccine against SARS-CoV 2. 5) Subjects with a history of having received a vaccine from the Cuban immunization scheme, in a period of less than 30 days prior to the administration of the investigational product . 6) Use of any investigational product in the 30 days prior to immunization. 7) Application of vaccines containing tetanus toxoid in the last 3 months. 8) Subjects with a history of major congenital malformations (defects that have an important functional compromise for the individual's life, have medical consequences and require early attention, sometimes urgently). 9) Primary or secondary immune system disease. 10) History of neoplastic disease. 11) History of severe allergic reactions. 12) Treatment with immunomodulators in the last 30 days (eg steroids (except topical and inhaled), Interferon, Immunoferon, Nasalferon, Transfer Factor, monoclonal antibody, Biomodulin T, any ganmaglobulin, Heberferon, Thymosin, Levamisole). 13) Subjects with a history of Convulsive Disease. 14) History of treatment with blood products such as blood cell, plasma, whole blood or platelet concentrate transfusions in the last 4 months. 15) Splenectomy or splenic dysfunction. 16) Pregnancy or lactation (a pregnancy test will be carried out before inclusion and administration of each dose to all girls and adolescents who menstruate). 17) Subjects with tattoos in the deltoid region of both arms. 18) Subjects with a history of HIV1 + 2 antibodies, hepatitis C antibodies, hepatitis B virus surface antigen, or VDRL serology. 19) History of psychoactive substance use in the last 6 months.

Type of population:

Children

Type of participant:

Healthy volunteers

Study design

Section to complete information about the characteristics of the study design.

Type study:

Interventional

Purpose:

Prevention

Allocation:

N/A: single arm study

Masking:

Open

Control group:

Uncontrolled

Study design:

Single group

Phase:

2

Target sample size:

425

Contact for public queries

Section to complete information about Email address, telephone number and postal address of the contact who will respond to general queries, including information about current recruitment status

First Name:

Beatriz

Last Name:

Paredes Moreno

Specialty:

Pharmaceutical Sciences

Affiliation:

Finlay Vaccine Institute

Postal Address:

21 avenue between 198 and 200 Atabey, Playa

City:

Havana

Country:

Cuba

Zip Code:

11600

Telephone:

+53-72718331

Email :

bparedes@finlay.edu.cu

Contact for scientific queries

Section to complete information about Email address, telephone number and postal address of the contact who will respond to scientific queries.

First Name:

Meiby

Middle Name:

de la Caridad

Last Name:

Rodriguez Gonzalez

Specialty:

First degree specialist in Integral General Medicine. Master in Epidemiology

Affiliation:

Finlay Vaccine Institute

Postal Address:

21 avenue between 198 and 200 Atabey, Playa

City:

Havana

Country:

Cuba

Zip Code:

11600

Telephone:

+53-72718331

Email :

mcrodriguez@finlay.edu.cu

Research Ethics Committees

Section to complete the data related to the review ethics committees.

Name of Research Ethics Committees:

Pediatric Hospital "Juan Manuel Márquez"

Status of evaluation:

Approved

Status of evaluation date of Ethic Committee:

15/07/2021

Postal address of Ethic Committee :

31 Av. corner 76, Marianao, Havana, ZC 11500, Cuba

Telephone:

+53-72606140

Email:

direccionjmm@pejm.sld.cu

About study completion

Section to complete the data related to the study completion.

Study completion date:

22/01/2022

Registration and Update

Section to complete information about the name of Primary Registry, date of registration and the unique ID number assigned by the registry (RPCEC).

Primary registry:

RPCEC

Unique ID number:

RPCEC00000384

Date of Registration in Primary Registry:

23/07/2021

Record Verification Date:

2021/08/09

Next update date:

2022/08/09

Link to the spanish version:

Click here

19 July 2023 - 2:55pm by Gladys		8 January 2026 - 5:56am by Gladys
< previous diff
No visible changes

Registered Trials

Registration process

SOBERANA PEDIATRIA CLINICA 1

About the RPCEC

Useful resources